ReadyGo Diagnostics

Executive Summary

ReadyGo Diagnostics is a UK-based biotechnology company founded in 2019 that is developing smart sample-to-test solutions using advanced engineered materials. Its platform automates sample collection, stabilization, and preparation from saliva, blood, or urine, enabling rapid and reliable diagnostics in decentralized settings. The technology aims to simplify testing for healthcare, public health, and other industries by reducing the need for complex laboratory infrastructure. By leveraging innovative materials for sample handling, ReadyGo seeks to address key bottlenecks in diagnostic workflows, particularly in point-of-care and remote environments. The company's approach has the potential to improve access to testing, reduce turnaround times, and lower costs, making diagnostics more accessible globally. While still in early stages with no publicly disclosed funding rounds or commercial products, ReadyGo Diagnostics is positioned in a growing market for decentralized diagnostics. The COVID-19 pandemic highlighted the need for scalable, user-friendly testing solutions, and the company's platform could be applicable to infectious diseases, chronic disease monitoring, and other applications. Success will depend on clinical validation, regulatory approvals, and strategic partnerships to commercialize its technology. Given the competitive landscape and the challenges of bringing novel diagnostic tools to market, the company faces significant hurdles but has a compelling value proposition if its platform can demonstrate robust performance in real-world settings.

Upcoming Catalysts (preview)

• Q4 2026Completion of pivotal clinical study for lead diagnostic test60% success
• H1 2027Securing CE marking under IVDR for first product50% success
• Q2 2027Announcing strategic partnership with global diagnostics distributor40% success